Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Bisphosphonates in malignant hypercalcemia and bone pain].

Olivier Lamy1

  • 1Service de médecine A Département de médecine CHUV, Lausanne. olivier.lamy@chuv.hospvd.ch

Revue Medicale De La Suisse Romande
|April 21, 2004
PubMed
Summary

Hypercalcemia of malignancy (HM) is a serious complication of advanced cancer that causes debilitating symptoms. Early diagnosis and treatment with bisphosphonates, like zoledronate, significantly improve patient quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of reforms and work environment on resident time allocation in a Swiss internal medicine division: a time motion study with a before-and-after comparison.

Swiss medical weekly·2026
Same author

Correction: Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Correction: A meta-analysis of previous falls and subsequent fracture risk in cohort studies.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Predictive value of BMD for hip and other fractures: a meta-analysis to update FRAX.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report.

Frontiers in endocrinology·2026
Same author

A meta-analysis of smoking and fracture risk to update the FRAX® tool.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026

Area of Science:

  • Oncology
  • Endocrinology
  • Skeletal Metastases

Context:

  • The skeleton is the most frequent site of cancer metastasis.
  • Hypercalcemia of malignancy (HM) affects 10-20% of patients with advanced cancer.
  • HM significantly decreases quality of life due to symptoms like bone pain, nausea, confusion, and polyuria.

Purpose:

  • To highlight the underdiagnosis and undertreatment of HM.
  • To emphasize HM as a medical emergency requiring prompt intervention.
  • To discuss current and optimal treatment strategies for HM and metastatic bone disease.

Summary:

  • HM presents with various symptoms that improve with calcemia normalization.
  • Treatment involves rapid rehydration with isotonic saline and intravenous bisphosphonates.
  • Bisphosphonates are crucial for managing complications of metastatic bone disease, including HM.

Impact:

  • Early diagnosis and treatment of HM can significantly improve patient outcomes and quality of life.
  • Zoledronate is established as the standard of care for HM and metastatic bone disease due to its efficacy and convenience.
  • Effective management of bone metastases reduces complications such as pathological fractures and spinal cord compression.

Related Experiment Videos